Hydron;6-(imidazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid;chloride | 97901-22-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: Hydron;6-(imidazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid;chloride
• 英文别名: hydron;6-(imidazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid;chloride
• CAS: 97901-22-9
• 化学式: C15H17ClN2O2
• 分子量: 292.76
• InChiKey: DRWRJLPMUWWEHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.81
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 6-<(tosyloxy)methyl>-5,6,7,8-tetrahydronaphthalene-2-carboxylate 以93的产率得到Hydron;6-(imidazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid;chloride
  参考文献：
  名称：

  J. Med. Chem. 1989, 32, 1326-1334

  摘要：

  DOI：

文献信息

• Inhibitor of restenosis after percutaneous transluminal coronary angioplasty
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP0385381A2

  公开（公告）日：1990-09-05

  A restenosis inhibiting agent for the treatment or prevention of restenosis after percutaneous transluminal coronary angioplasty which comprises a pharmaceutically effective amount of a compound of the following general formula or a pharmaceutically acceptable salt thereof as an active ingredient: wherein R is an imidazolyl group, a thiazolyl group or a pyridyl group, n is an integer of 1 or 2, and m is an integer of 1 to 4.

  一种用于治疗或预防经皮冠状动脉腔内成形术后再狭窄的再狭窄抑制剂，其活性成分包括药学上有效量的下式通式化合物或其药学上可接受的盐： 其中 R 是咪唑基团、噻唑基团或吡啶基团，n 是 1 或 2 的整数，m 是 1 至 4 的整数。
• AGENT FOR PREVENTION AND DEPRESSION OF DRY COUGHING CAUSED BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS
  申请人：KISSEI PHARMACEUTICAL CO., LTD.

  公开号：EP0875254A1

  公开（公告）日：1998-11-04

  The present invention is to provide an agent for the prevention and depression of dry coughing caused by angiotensin converting enzyme inhibitors which comprises a thromboxane synthetase inhibitor or thromboxane receptor antagonist as the active ingredient. Administering the drug is effective in preventing and depressing dry coughing caused by angiotensin converting enzyme inhibitors. For example, the use of the drug in combination with ozagrel hydrochloride was found to be effective in significantly dry coughing in hypertonic patients suffering from dry coughing attributable to the administration of captopril.

  本发明旨在提供一种预防和抑制由血管紧张素转换酶抑制剂引起的干咳的药物，其活性成分包括血栓素合成酶抑制剂或血栓素受体拮抗剂。服用该药物可有效预防和抑制血管紧张素转换酶抑制剂引起的干咳。例如，对于因服用卡托普利而引起干咳的高渗患者，将该药物与盐酸奥扎格雷联合使用可有效明显缓解干咳。
• Benzocycloalkane derivatives
  申请人：DAIICHI SEIYAKU CO., LTD.

  公开号：EP0135177B1

  公开（公告）日：1989-12-06
• Treating agent for Raynaud's disease
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP0346929B1

  公开（公告）日：1994-04-27
• US4665188A
  申请人：——

  公开号：US4665188A

  公开（公告）日：1987-05-12